Arcutis Biotherapeutics ( (ARQT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcutis Biotherapeutics shares climbed after Wall Street analysts reiterated their bullish stance on the company. Guggenheim reaffirmed its Buy rating, highlighting a positive outlook for the business, while BTIG also restated its Buy rating, reinforcing strong investor confidence. Following these calls, Guggenheim set a price target of $34 and BTIG set theirs at $31. The stock last closed at $28.01, and the average analyst target of $30.25 still points to further upside, supported by an overall Strong Buy consensus.
More about Arcutis Biotherapeutics
YTD Price Performance: 92.38%
Average Trading Volume: 2,435,930
Technical Sentiment Signal: Buy
Current Market Cap: $3.43B
For further insights into ARQT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.